Published June 5, 2015 | Version v1
Journal article

Role of PTEN in TNFα induced insulin resistance

  • 1. National Institute of Diabetes & Digestive & Kidney Disease, National Institutes of Health, Bethesda, MD 20892 (United States)
  • 2. Wellcome Trust Medical Research Council Institute of Metabolic Science, Cambridge CB2 0QQ (United Kingdom)
  • 3. Medicine and Research Services, Veterans Association Medical Center, Memphis, TN 38104 (United States)
  • 4. Departments of Medicine and Pharmacology, University of Tennessee Health Science Center, Memphis, TN 38163 (United States)

Description

Aims/hypothesis: PTEN may play a reversible role in TNFα induced insulin resistance, which has been linked to obesity-associated insulin resistance (IR). Methods: Western blots for PTEN and p-Akt were performed on H-411E liver cells incubated with insulin, TNFα, and in selected experiments VO-OHpic vanadium complex in the presence and absence of PTEN siRNA. Total PTEN was compared to β-actin loading control and p-Akt was compared to total Akt. Results: Western blot and Real Time RT-PCR experiments showed increased PTEN after TNFα treatment (p = 0.04); slightly decreased PTEN after insulin treatment; and slightly increased PTEN after insulin + TNFα treatment. PTEN siRNA markedly inhibited the TNFα-induced increase in PTEN (p < 0.01) without significantly changing the p-Akt levels. The vanadium complex, exhibiting insulin-like effects, also significantly prevented the TNFα-induced increase in PTEN. Combining insulin and VO-OHpic was additive, providing both proof of concept and insight into mechanism. Discussion: The PTEN increase due to TNFα treatment was reversible by both PTEN siRNA knockdown and VO-OHpic treatment. Thus, PTEN is identified as a potential new therapeutic target for reducing IR in Type 2 DM. - Highlights: • TNFα treatment induced a significant increase in PTEN in H-411E liver cells. • PTEN siRNA knockdown prevented this effect. • VO-OHpic (vanadium complex) treatment, like insulin, decreased PTEN protein levels. • Thus, PTEN is identified as a potential therapeutic target in DM Type 2

Availability note (English)

Available from http://dx.doi.org/10.1016/j.bbrc.2015.04.063

Additional details

Identifiers

DOI
10.1016/j.bbrc.2015.04.063;
PII
S0006-291X(15)00753-6;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
461
Journal Issue
3
Journal Page Range
p. 533-536
ISSN
0006-291X
CODEN
BBRCA9

Optional Information

Copyright
Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.